HemoCath pioneers advancements at the crossroads of Medtech and Digital Health, aiming to enhance care for individuals with heart failure (HF). The versatile and scalable HemoCath AI Platform enables proactive AI-data-driven management of patients with acute HF from diagnosis to treatment and monitoring for all hospital heart procedures. The user-friendly integrated Platform includes the HemoCath PA catheter securely connected to the Luc AI Cloud to continuously measure and monitor PAP & CVP, the leading indicators of heart congestion, allowing early targeted therapy. The vital health information remains easily available to the managing clinician, supporting optimal dosing of guideline-directed medical therapy (GDMT) across the entire spectrum of HF. Several clinical trials provide clinical evidence of a significant improvement in cardiac care and reduction in hospital stay with PAP-guided HF management. Learn more at www.hemocath.com